- Home
- NCA vs DCTH Comparison
NCA vs DCTH Comparison
Compare NCA & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCA
- DCTH
- Stock Information
- Founded
- NCA 1987
- DCTH 1988
- Country
- NCA United States
- DCTH United States
- Employees
- NCA N/A
- DCTH N/A
- Industry
- NCA Investment Managers
- DCTH Medical/Dental Instruments
- Sector
- NCA Finance
- DCTH Health Care
- Exchange
- NCA Nasdaq
- DCTH Nasdaq
- Market Cap
- NCA 288.4M
- DCTH 379.5M
- IPO Year
- NCA N/A
- DCTH N/A
- Fundamental
- Price
- NCA $8.83
- DCTH $12.27
- Analyst Decision
- NCA
- DCTH Strong Buy
- Analyst Count
- NCA 0
- DCTH 4
- Target Price
- NCA N/A
- DCTH $21.50
- AVG Volume (30 Days)
- NCA 59.6K
- DCTH 389.6K
- Earning Date
- NCA 01-01-0001
- DCTH 11-08-2024
- Dividend Yield
- NCA 3.92%
- DCTH N/A
- EPS Growth
- NCA N/A
- DCTH N/A
- EPS
- NCA N/A
- DCTH N/A
- Revenue
- NCA N/A
- DCTH $22,644,000.00
- Revenue This Year
- NCA N/A
- DCTH $1,605.13
- Revenue Next Year
- NCA N/A
- DCTH $111.67
- P/E Ratio
- NCA N/A
- DCTH N/A
- Revenue Growth
- NCA N/A
- DCTH 945.91
- 52 Week Low
- NCA $7.77
- DCTH $3.10
- 52 Week High
- NCA $9.12
- DCTH $12.88
- Technical
- Relative Strength Index (RSI)
- NCA 53.66
- DCTH 63.93
- Support Level
- NCA $8.64
- DCTH $11.36
- Resistance Level
- NCA $8.82
- DCTH $12.10
- Average True Range (ATR)
- NCA 0.08
- DCTH 0.69
- MACD
- NCA 0.02
- DCTH 0.10
- Stochastic Oscillator
- NCA 82.61
- DCTH 84.97
About NCA Nuveen California Municipal Value Fund
Nuveen California Municipal Value Fund Inc is a diversified closed-end management investment company. Its primary objective is to provide current income exempt from regular federal and California income taxes. The fund's secondary objective is to enhance portfolio value relative to the California municipal bond market by investing in tax-exempt California municipal securities that the Fund's investment adviser and/or the Fund's sub-adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.